Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
Cullinan Oncology(US:CGEM) Newsfilter·2024-04-24 22:09CLN-619介绍 - Cullinan Therapeutics宣布将在2024年美国临床肿瘤学会年会上展示CLN-619在晚期实体瘤患者中的临床数据[1] - CLN-619是一种新颖的潜在一类抗体，通过多种机制发挥作用，为与检查点抑制剂等免疫疗法结合提供机会[2] - CLN-619是一种人源化IgG1单克隆抗体，通过恢复肿瘤细胞表面的MICA/B表达，促进NKG2D介导的免疫激活，从而通过多种免疫介导机制促进抗肿瘤活性[4]